A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Authors: Mazyar Shadman, Keri Yang, Sheng Xu, Rhys Williams, Tahla Munir
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.e19031
Source:
Full article
Abstract
e19031